NASDAQ:TBPH - Theravance Biopharma Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.44
  • Forecasted Upside: 62.25 %
  • Number of Analysts: 9
  • Breakdown:
  • 3 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.67
▼ -0.18 (-2.29%)

This chart shows the closing price for TBPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Theravance Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TBPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TBPH

Analyst Price Target is $12.44
▲ +62.25% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Theravance Biopharma in the last 3 months. The average price target is $12.44, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 62.25% upside from the last price of $7.67.

This chart shows the closing price for TBPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Theravance Biopharma. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 2 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 3 sell ratings
9/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 3 sell ratings
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2021SVB LeerinkLower Price TargetOutperform$29.00 ➝ $10.00Low
9/16/2021Morgan StanleyLower Price TargetUnderweight$14.00 ➝ $10.00Low
9/16/2021Robert W. BairdLower Price TargetNeutral$10.00 ➝ $7.00Low
9/16/2021HC WainwrightLower Price TargetBuy$21.00 ➝ $8.00Low
9/15/2021CowenLower Price TargetMarket Perform$14.00 ➝ $8.00Low
9/15/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
9/15/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$7.00High
8/24/2021Morgan StanleyDowngradeOverweight ➝ Underweight$27.00 ➝ $14.00High
8/24/2021SVB LeerinkLower Price TargetOutperform$37.00 ➝ $29.00High
8/24/2021Needham & Company LLCLower Price TargetBuy$32.00 ➝ $18.00High
8/24/2021Robert W. BairdLower Price TargetNeutral$20.00 ➝ $10.00High
8/24/2021HC WainwrightLower Price TargetBuy$32.00 ➝ $21.00High
8/24/2021CitigroupLower Price TargetUnderperform$20.00 ➝ $14.00High
8/24/2021CowenDowngradeOutperform ➝ Market Perform$42.00 ➝ $14.00High
8/4/2021SVB LeerinkBoost Price TargetOutperform$36.00 ➝ $37.00High
7/16/2021Morgan StanleyLower Price TargetOverweight$28.00 ➝ $27.00Medium
6/28/2021SVB LeerinkLower Price TargetOutperform$39.00 ➝ $36.00Low
6/23/2021SVB LeerinkReiterated RatingBuyMedium
5/13/2021Morgan StanleyLower Price TargetOverweight$30.00 ➝ $28.00High
5/5/2021SVB LeerinkLower Price TargetOutperform$40.00 ➝ $39.00Medium
5/5/2021Needham & Company LLCLower Price TargetBuy$40.00 ➝ $32.00Medium
4/1/2021SVB LeerinkLower Price TargetOutperform$41.00 ➝ $40.00Medium
3/1/2021Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00Low
2/24/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$35.00 ➝ $41.00High
12/16/2020Morgan StanleyLower Price TargetOverweight$32.00 ➝ $31.00Low
11/23/2020Evercore ISIReiterated RatingOutperform$30.00Medium
11/6/2020HC WainwrightReiterated RatingBuyHigh
11/6/2020SVB LeerinkLower Price TargetOutperform$40.00 ➝ $35.00High
10/14/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$32.00High
8/10/2020Morgan StanleyLower Price TargetEqual Weight$30.00 ➝ $29.00Low
8/7/2020Piper SandlerLower Price TargetOverweight$35.00 ➝ $30.00Low
7/7/2020JPMorgan Chase & Co.Initiated CoverageOverweight$29.00High
6/15/2020Morgan StanleyInitiated CoverageEqual Weight$30.00High
5/13/2020CowenInitiated CoverageOutperform$42.00High
5/7/2020HC WainwrightReiterated RatingBuy$32.00High
4/23/2020HC WainwrightReiterated RatingBuy$32.00Low
2/25/2020HC WainwrightBoost Price TargetBuy$30.00 ➝ $32.00Medium
2/25/2020Piper SandlerLower Price TargetOverweight$40.00 ➝ $35.00High
1/8/2020HC WainwrightBoost Price TargetBuy$25.00 ➝ $30.00High
11/6/2019Piper Jaffray CompaniesLower Price TargetOverweight$55.00 ➝ $40.00Low
11/6/2019Robert W. BairdUpgradeUnderperform ➝ Neutral$22.00 ➝ $18.00Low
10/29/2019HC WainwrightInitiated CoverageBuy$25.00Low
9/9/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/16/2019Cantor FitzgeraldSet Price TargetBuy$55.00Low
7/31/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00N/A
6/19/2019Piper Jaffray CompaniesReiterated RatingPositive$55.00Medium
4/12/2019Cantor FitzgeraldReiterated RatingBuy$55.00Low
3/28/2019Cantor FitzgeraldReiterated RatingBuy$55.00Low
2/26/2019Cantor FitzgeraldReiterated RatingBuy$55.00Low
1/28/2019Cantor FitzgeraldInitiated CoverageBuy$55.00High
11/9/2018Cantor FitzgeraldReiterated RatingBuy$55.00Low
11/7/2018SVB LeerinkSet Price TargetBuy$38.00Medium
10/23/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
10/22/2018Cantor FitzgeraldReiterated RatingBuy$55.00High
8/1/2018Piper Jaffray CompaniesReiterated RatingOverweight$55.00Medium
8/1/2018Cantor FitzgeraldSet Price TargetBuy$55.00Low
8/1/2018Needham & Company LLCReiterated RatingBuy$40.00Low
5/24/2018Cantor FitzgeraldSet Price TargetBuy$55.00Medium
5/9/2018Needham & Company LLCReiterated RatingBuy$40.00Low
5/9/2018SVB LeerinkSet Price TargetBuy$41.00 ➝ $31.00High
5/8/2018Cantor FitzgeraldSet Price TargetBuy$55.00High
3/29/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$45.00Medium
2/27/2018Cantor FitzgeraldSet Price TargetBuy$55.00High
2/8/2018SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $48.00Medium
12/5/2017Needham & Company LLCReiterated RatingBuyHigh
11/7/2017Cantor FitzgeraldReiterated RatingBuy$55.00N/A
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/A
10/25/2017Cantor FitzgeraldSet Price TargetBuy$55.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$55.00Low
9/19/2017Cantor FitzgeraldReiterated RatingBuy$55.00Low
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$45.00Medium
8/16/2017Cantor FitzgeraldSet Price TargetBuy$55.00Low
8/2/2017Needham & Company LLCReiterated RatingBuyHigh
7/19/2017Cantor FitzgeraldSet Price TargetBuy$55.00High
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$55.00High
5/11/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.00Low
5/10/2017SVB LeerinkSet Price TargetBuy$47.00Low
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$42.00Medium
2/28/2017Needham & Company LLCReiterated RatingBuy$40.00N/A
12/21/2016Needham & Company LLCInitiated CoverageBuy$40.00N/A
11/9/2016SVB LeerinkReiterated RatingBuy$33.00N/A
11/3/2016Piper Jaffray CompaniesInitiated CoverageOverweight$42.00N/A
10/31/2016SVB LeerinkReiterated RatingOutperform$35.00 ➝ $33.00N/A
(Data available from 10/27/2016 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
9/27/2021
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Theravance Biopharma logo
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.
Read More

Today's Range

Now: $7.67
Low: $7.67
High: $7.95

50 Day Range

MA: $9.01
Low: $6.77
High: $14.17

52 Week Range

Now: $7.67
Low: $6.10
High: $22.74

Volume

298,711 shs

Average Volume

669,971 shs

Market Capitalization

$563.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Theravance Biopharma?

The following Wall Street research analysts have issued research reports on Theravance Biopharma in the last twelve months: Citigroup Inc., Cowen Inc, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Robert W. Baird, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for TBPH.

What is the current price target for Theravance Biopharma?

9 Wall Street analysts have set twelve-month price targets for Theravance Biopharma in the last year. Their average twelve-month price target is $12.44, suggesting a possible upside of 58.5%. Evercore ISI has the highest price target set, predicting TBPH will reach $30.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $7.00 for Theravance Biopharma in the next year.
View the latest price targets for TBPH.

What is the current consensus analyst rating for Theravance Biopharma?

Theravance Biopharma currently has 3 sell ratings, 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TBPH, but not buy more shares or sell existing shares.
View the latest ratings for TBPH.

How do I contact Theravance Biopharma's investor relations team?

Theravance Biopharma's physical mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company's listed phone number is (650) 808-6000 and its investor relations email address is [email protected] The official website for Theravance Biopharma is www.theravance.com.